Stock Track | Trevi Therapeutics Soars 7.15% in Pre-Market on Positive Analyst Coverage

Stock Track

Mar 18

Trevi Therapeutics Inc. (TRVI) experienced a significant pre-market surge of 7.15% on Wednesday, indicating strong investor optimism ahead of the regular trading session.

The upward movement appears to be driven by recent analyst actions. Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on the stock and set a price target of $18.00, reinforcing positive sentiment towards the company's prospects.

Concurrently, Morgan Stanley adjusted its outlook, cutting its price target on Trevi Therapeutics to $18.00 from $19.00. Despite the reduction, the maintained target price suggests continued analyst confidence in the stock's value, contributing to the pre-market rally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1119380775"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1119380775\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1119380775?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 21:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119380775","market":"nz","top_or_hot":-1,"title":"Stock Track | Trevi Therapeutics Soars 7.15% in Pre-Market on Positive Analyst Coverage","media":"Stock Track","content":"<p>Trevi Therapeutics Inc. (TRVI) experienced a significant pre-market surge of 7.15% on Wednesday, indicating strong investor optimism ahead of the regular trading session.</p><p>The upward movement appears to be driven by recent analyst actions. Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on the stock and set a price target of $18.00, reinforcing positive sentiment towards the company's prospects.</p><p>Concurrently, Morgan Stanley adjusted its outlook, cutting its price target on Trevi Therapeutics to $18.00 from $19.00. Despite the reduction, the maintained target price suggests continued analyst confidence in the stock's value, contributing to the pre-market rally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Trevi Therapeutics Soars 7.15% in Pre-Market on Positive Analyst Coverage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Trevi Therapeutics Soars 7.15% in Pre-Market on Positive Analyst Coverage\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-18 21:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Trevi Therapeutics Inc. (TRVI) experienced a significant pre-market surge of 7.15% on Wednesday, indicating strong investor optimism ahead of the regular trading session.</p><p>The upward movement appears to be driven by recent analyst actions. Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on the stock and set a price target of $18.00, reinforcing positive sentiment towards the company's prospects.</p><p>Concurrently, Morgan Stanley adjusted its outlook, cutting its price target on Trevi Therapeutics to $18.00 from $19.00. Despite the reduction, the maintained target price suggests continued analyst confidence in the stock's value, contributing to the pre-market rally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TRVI","symbol_name":"Trevi Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1119380775","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119380775","pubTimestamp":1773840411,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Trevi Therapeutics Inc. (TRVI) experienced a significant pre-market surge of 7.15% on Wednesday, indicating strong investor optimism ahead of the regular trading session.The upward movement appears...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TRVI":"Trevi Therapeutics Inc."},"translate_title":"个股追踪|分析师正面报道Trevi Therapeutics盘前大涨7.15%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRVI":1},"content_text":"Trevi Therapeutics Inc. (TRVI) experienced a significant pre-market surge of 7.15% on Wednesday, indicating strong investor optimism ahead of the regular trading session.The upward movement appears to be driven by recent analyst actions. Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on the stock and set a price target of $18.00, reinforcing positive sentiment towards the company's prospects.Concurrently, Morgan Stanley adjusted its outlook, cutting its price target on Trevi Therapeutics to $18.00 from $19.00. Despite the reduction, the maintained target price suggests continued analyst confidence in the stock's value, contributing to the pre-market rally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}